Prostate cancer (PC) is the most common cancer in men and the second leading cause of
cancer-related death worldwide. Many therapeutic advances over the last two decades have …

Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3)(also called VEGFR-3) is
activated by its specific ligand, VEGF-C, which promotes cancer progression. The VEGF …

Objective The practice of early burn wound excision and wound closure by immediate
autologous skin or skin substitutes is the preferred treatment in extensive deep partial and …

Molecular markers have the potential to serve not only as prognostic factors but may be
targets for new therapeutic strategies and predictors of response in a range of cancers …

Dissemination to draining lymph nodes is a frequent first step in prostate cancer metastasis.
Although tumors metastasize to lymph nodes via the lymphatics, the importance of …

Angiogenesis, increased glycolysis, and cellular adaptation to hypoxic microenvironment
are characteristic of solid tumors, including prostate cancer. These representative features …

Detection of lymph node metastases indicates poor prognosis for prostate cancer patients.
Therefore, elucidation of the mechanism (s) of lymph node metastasis is important to …

Vascular endothelial growth factor C (VEGF-C) has been identified as a multifaceted factor
participating in the regulation of tumor angiogenesis and lymphangiogenesis. VEGF-C is not …

BACKGROUND Vascular endothelial growth factor C (VEGF‐C) and its receptor, VEGFR‐3,
have been implicated as important factors in the formation of lymphatic vessels and recent …

Prostate cancer, with a lifetime prevalence of one in six men, is the second cause of
malignancy-related death and the most prevalent cancer in men in many countries …